Evidence map›Paper›PMID 29627846›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2018

Upregulation of Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) Mediates the Reversal Effect of Verapamil on Chemo-Resistance to Adriamycin of Hepatocellular Carcinoma.

Guangshan Yang, Gaofei Fan, Tengyue Zhang, Kelong Ma, Jin Huang, Miao Liu, Xiaolu Teng, Kun Xu, Pingsheng Fan, Dongmiao Cheng

Open access · hybridAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. WDR20 prevents hepatocellular carcinoma senescence by orchestrating the simultaneous USP12/46-mediated deubiquitination of c-Myc.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  5. Review
  6. Article
  7. Article
  8. The multiple roles of deubiquitinases in liver cancer.American journal of cancer research · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Guangshan YangSchool of Clinical Medicine, Shan Dong University, Jinan, Shandong, China (mainland).
Gaofei FanThe Cancer Hospital of Anhui Province, Hefei, Anhui, China (mainland).
Tengyue ZhangThe Cancer Hospital of Anhui Province, Hefei, Anhui, China (mainland).
Kelong MaClinical College of Integrated Traditional Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei, Anhui, China (mainland).
Jin HuangThe Cancer Hospital of Anhui Province, Hefei, Anhui, China (mainland).
Miao LiuThe Cancer Hospital of Anhui Province, Hefei, Anhui, China (mainland).
Xiaolu TengThe Cancer Hospital of Anhui Province, Hefei, Anhui, China (mainland).
Kun XuThe Cancer Hospital of Anhui Province, Hefei, Anhui, China (mainland).
Pingsheng FanSchool of Clinical Medicine, Shan Dong University, Jinan, Shandong, China (mainland).
Dongmiao ChengDepartment of Radiotherapy, The First People's Hospital of Huainan City, Huainan, Anhui, China (mainland).
Anhui University of Traditional Chinese Medicine · CNHuainan Normal University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND The aim of this study was to investigate the role of ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) in the reversal effect of verapamil (VER) on chemo-resistance to Adriamycin (ADM) in treatment of hepatocellular carcinoma (HCC). MATERIAL AND METHODS HCC cell lines SMMC-7721 and BEL-7402 were used as model cell lines. High-throughput transcriptome sequencing based on Illumina technology was used to screen whether UCHL1 mediated the reversal effect of VER on chemo-resistance. Quantitative real-time PCR (qRT-PCR) was performed to determine the expression level of UCHL1 mRNA in HCC cells, and western blot analysis was performed to examine the protein expression of UCHL1 protein in HCC cells. Immunohistochemistry assay was performed to determine the protein expression of UCHL1 in tissue samples from patients presenting with either positive or negative responses to the reversal therapeutic regimen of VER. Moreover, cell models with UCHL1 knockdown and overexpression were established to examine the reversal effect of VER on chemo-resistance to ADM in HCC cells. Cell apoptosis was determined by flow cytometry following Annexin V-PI staining. RESULTS The expression levels of UCHL1 genes correlated with the level of apoptosis induced by ADM+VER. Overexpression of UCHL1 genes promoted apoptosis in cells treated with VER+ADM. UCHL1 knockdown using siRNA weakened the effect of ADM+VER, indicating that ADM+VER promotes HCC cell apoptosis and that UCHL1 genes participate in VER-mediated promotion in tumor cell apoptosis. CONCLUSIONS Upregulation of UCHL1 enhanced the reversal effect of VER on chemo-resistance to ADM and promoted cell apoptosis. The underlying mechanism of the function of UCHL1 and the signaling pathway involved in its effect are to be investigated in our future research.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsApoptosisCarcinoma, HepatocellularCell Line, TumorDoxorubicinDrug Resistance, NeoplasmDrug SynergismGene Knockdown TechniquesHep G2 CellsHumansLiver NeoplasmsRNA, Small InterferingSignal TransductionTranscriptomeUbiquitin ThiolesteraseUp-RegulationDoxorubicinRNA, Small InterferingUbiquitin carboxyl-Terminal Hydrolase L-1, humanUbiquitin ThiolesteraseVerapamil

Identifiers

PMID29627846
PMCPMC5909418
OpenAlexW2796322686

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.